Patent intelligence · US
US 11285194
Combination immunotherapy approach for treatment of cancer
Combination immunotherapy approach for treatment of cancer
Patent details — US 11285194
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 29, 2022
- Expiration
- Mar 24, 2042
- Applicant
- Calidi Biotherapeutics, Inc.
- Claims
- 16
- CPC classes
- A61K, A61K2039/572, A61K31/00, A61K35/12
Quick answer
US 11285194 (Combination immunotherapy approach for treatment of cancer) is held by Calidi Biotherapeutics, Inc.. Status: granted. Granted Mar 29, 2022. Expires Mar 24, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Calidi Biotherapeutics, Inc.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K2039/572, A61K31/00, A61K35/12, A61K35/28, A61K35/30
More from Calidi Biotherapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12036278
Smallpox vaccine for cancer treatment
granted -
US 11655455
Enhanced systems for cell-mediated oncolytic viral therapy
granted -
US 11607450
Smallpox vaccine for cancer treatment
granted -
US 11505782
Cell-based vehicles for potentiation of viral therapy
granted -
US 10857225
Smallpox vaccine for cancer treatment
granted -
US 10105436
Smallpox vaccine for cancer treatment
granted
Frequently asked questions
What is US patent 11285194?
US 11285194 (Combination immunotherapy approach for treatment of cancer) is held by Calidi Biotherapeutics, Inc.. Status: granted. Granted Mar 29, 2022. Expires Mar 24, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11285194?
Calidi Biotherapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 11285194 expire?
Our index shows an expiration date of Mar 24, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.